An MVA vaccine overcomes tolerance to human p53 in mice and humans.
about
Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccinesModified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model.p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responsesRecombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion.Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimenHeterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression.A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector.A novel approach to evaluate the immunogenicity of viral antigens of clinical importance in HLA transgenic murine models.A safety-modified SV40 Tag developed for human cancer immunotherapy.Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer.Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy.p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy.Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab.
P2860
Q33653229-8B1EB21E-14F0-4A7D-BABE-EF6F8A697D4DQ33723063-0E06574F-C81F-4246-9517-AD883396FEEFQ34135426-EB39910E-94C2-4C24-855A-5E4FEDF5E8B8Q35677112-86CEDB68-8AA3-4E6D-A7B6-94307BC59DF6Q36456190-EEB86E31-93FA-4A98-B3DA-8886435994E4Q36469826-B05D945A-84FC-4D31-AB7D-F6A6D2FFA05DQ36824066-BD7894A8-0DDE-4526-AA15-E740137DF79BQ36960608-2FFE1ADA-6FE5-4631-B54C-9CF925ACEAE3Q37385602-0396CC1A-6803-4D81-A7B2-4C02F7B605FFQ37997734-8BB17739-5C4E-4444-AB44-E867AB5A3385Q45025116-953D1FA7-419B-402B-82CF-B97B22B94026Q47561666-ADACB2A2-51BB-44E0-9FF7-5CE3595105B5Q47563512-B2B780FD-85EB-42F7-B43F-C2AD980C9A8D
P2860
An MVA vaccine overcomes tolerance to human p53 in mice and humans.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
An MVA vaccine overcomes tolerance to human p53 in mice and humans.
@ast
An MVA vaccine overcomes tolerance to human p53 in mice and humans.
@en
An MVA vaccine overcomes tolerance to human p53 in mice and humans.
@nl
type
label
An MVA vaccine overcomes tolerance to human p53 in mice and humans.
@ast
An MVA vaccine overcomes tolerance to human p53 in mice and humans.
@en
An MVA vaccine overcomes tolerance to human p53 in mice and humans.
@nl
prefLabel
An MVA vaccine overcomes tolerance to human p53 in mice and humans.
@ast
An MVA vaccine overcomes tolerance to human p53 in mice and humans.
@en
An MVA vaccine overcomes tolerance to human p53 in mice and humans.
@nl
P2093
P2860
P1476
An MVA vaccine overcomes tolerance to human p53 in mice and humans.
@en
P2093
Eric C C Huang
Glen Gibson
Guang-Yun Song
Joshua D I Ellenhorn
Monica Hollstein
Pirouz Daftarian
Tumul Srivasta
Wahajul Haq
Zhongde Wang
P2860
P2888
P304
P356
10.1007/S00262-006-0270-3
P577
2007-01-12T00:00:00Z
P5875
P6179
1041195228